Abstract:Acute myeloid leukemia (AML) with t(6;9)(p22;q34) is listed as a distinct entity in the 2016 WHO Classification of Tumors of Heamatopoetic and Lymphoid Tissues, but the clinical features and prognostic impact are still not well established. We retrospectively reviewed 1620 AML patients diagnosed from the year 2013 to 2019 and 15 patients with t(6;9)(p22;q34) were identified. Their morphology, immunophenotype, cytogenetics, molecular findings, treatment and prognosis were analyzed. The incidence of AML with t(6;9)(p22;q34) is 0.9% (15/1620). There was 10 women and 5 men (ratio, 2:1) with a median age of 39 years (range:16-64). The median WBC count at diagnosis was 9.72×109/L(range: 1.78-45.4). According to French-American- British classification, 10 (66.7%) were M5 and 5 were M4. At cytogenetic level, t(6;9)(p22;q34) was the sole cytogenetic abnormality in 12 patients (80%) while 2 had one additional aberration and 1 presented with a complex karyotype. Molecular studies using next generation sequencing showed a unique mutation profile characterized by a high frequency of FLT3 mutations (10/13, 77%) including 9 cases with ITD and 1 case with TKD. Other mutations included RAS (3 NRAS and 2 KRAS) (5/13), FAT1 (4/13), NOTCH1 and PRDM1 (2/13 respectively). However, the common mutations of AML, such DNMT3A and NPM1, were rare in this subtype. The median number of mutated genes was 3 (range:1-6). Among the 9 patients with FLT3-ITD, FLT3-ITD ratio was measured in 5 patients and all showed a high ratio (median: 0.62, range: 0.59-1.11). All patients received induction chemotherapy; 12 (80%) patients achieved complete remission (CR) after one or two cycles of induction. Among these 15 patients, 7 underwent allogenic stem cell transplant (SCT) and all were alive in CR status at the last follow-up (median OS: 32.9 mon). In contrast, among the 8 patients who did not receive SCT, 5 died of disease relapse and the remaining 3 patients were newly diagnosed with a relatively short follow-up time (median OS: 10.4mon). In conclusion, t(6;9)/DEK-NUP214 AML represents a unique subtype of AML, with unique gene expression profiling (a high frequency of FLT3-ITD). Most patients can achieve CR after chemotherapy, allo-SCT can improve long term survival.

Clinical Analysis of Acute Myeloid Leukemia with Inv(16)/t(16;16)

Clinical analysis on 15 acute myeloid leukemia patients with 11p15 abnormalities

Prognosis Influence of Additional Chromosome Abnormalities in Newly Diagnosed Acute Promyelocytic Leukemia with T(15;17)(q24;q21)

[Analysis of Age-Specific Cytogenetic Changes among 515 Patients Withacute Myeloid Leukemia].

[Clinical features and prognosis of acute myeloid leukemia with acquired trisomy 21].

Retrospective Analysis of 59 Cases Flt3-Itd Mutation Positive Acute Myeloid Leukemia

Clinical and Laboratory Features of Pediatric Acute Myeloid Leukemia with Inversion of Chromosome 16

Clinical Characteristics of Acute Myeloid Leukemia with T(16;21)(p11;q22):Nine Cases Report and Literature Review

[Clinical Features and Prognosis of Acute Myeloid Leukemia-M(4).].

[Clinical and Laboratorial Characteristics of Primary Acute Myeloid Leukemia with Philadelphia Chromosome and Inversion 16].

Outcome and Prognostic Factors of CBF Pediatric AML Patients with T(8;21) Differ from Patients with Inv(16)

Clinical Characteristics and Prognostic Factors Analysis of Core Binding Factor Acute Myeloid Leukemia in Real World.

[Relationship Between RAD51-g135C and XRCC3-C241T Polymorphisms and Prognosis of Inv (16)/ T(16;16) (Cbfbeta-Myh11) Acute Myeloid Leukemia].

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Risk stratification and analysis of prognostic factors of acute myeloid leukemia with t(8;21)

Analysis of Clinical Features and Prognosis in Patients with Refractory/Relapsed Acute Myeloid Leukemia- Results from Our Center

Favorable Outcome Of Allogenic Stem Cell Transplant In Patients With Acute Myeloid Leukemia Carrying T(6;9)(P22;Q34) / Dek-Nup214 Rearrangement

[Clinical and Experimental Characteristics of 20 Patients with Acute Myeloid Leukemia with Complex Variant of T(8; 21)].

Clinical Analysis of Cytogenetic Features in Acute Myeloid Leukemia and Its Relationship with Early Responses after Induction Therapy

[Clinical Features and Prognosis of T (8; 21)/Aml1-Eto-positive Childhood Acute Myeloid Leukemia].

[Analysis of Prognostic Variables in Childhood Acute Myeloid Leukemia].